Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
65 studies found for:    Open Studies | "Epstein-Barr Virus Infections"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Genetic Studies of Chronic Active Epstein-Barr Disease
Condition: Epstein-Barr Virus Infections
Intervention:
2 Recruiting Mental Training for CFS Following EBV Infection in Adolescents
Conditions: Fatigue Syndrome, Chronic;   Epstein-Barr Virus Infection
Intervention: Behavioral: Mental training
3 Recruiting A Study of the Safety and Efficacy of EBV Specific T-cell Lines
Conditions: Epstein-Barr Virus Infections;   Post-Transplant Lymphoproliferative Disorder;   Lymphoma
Interventions: Biological: Group A;   Biological: Group B
4 Recruiting ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Conditions: Transplantation Infection;   Epstein-Barr Virus Infections;   Cytomegalovirus Infections
Interventions: Drug: Valacyclovir;   Drug: Valganciclovir
5 Recruiting Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against Epstein Barr Virus, Adenovirus, And Cytomegalovirus
Conditions: Epstein-Barr Virus Infections;   Adenovirus;   Cytomegalovirus Infections
Intervention: Biological: Cytotoxic T Lymphocytes
6 Recruiting Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Conditions: Epstein-Barr Virus Infection;   Stage II Nasopharyngeal Carcinoma;   Stage III Nasopharyngeal Carcinoma;   Stage IVA Nasopharyngeal Carcinoma;   Stage IVB Nasopharyngeal Carcinoma
Interventions: Drug: Cisplatin;   Other: Clinical Observation;   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
7 Recruiting Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients
Condition: Lymphoproliferative Disorders
Intervention: Other: Determining the source of EBV in severe EBV infections
8 Recruiting Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
Conditions: Hodgkin Disease;   Non Hodgkin Lymphoma;   Lymphoepithelioma;   Severe Chronic Active EBV Infection Syndrome (SCAEBV);   Leiomyosarcoma
Interventions: Drug: LMP1/2 CTLs (Group A);   Drug: LMP1/2 CTLs (Group B)
9 Recruiting Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O)
Condition: Leukemia
Interventions: Drug: Ofatumumab;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: G-CSF;   Behavioral: Phone Calls
10 Recruiting The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department
Conditions: Infectious Mononucleosis;   Splenomegaly
Intervention: Device: Point-of-care ultrasound
11 Recruiting High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Conditions: Post-Transplant Lymphoproliferative Disorder;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Radiation: Indium In-111 Ibritumomab Tiuxetan;   Drug: Mycophenolate Mofetil;   Other: Pharmacological Study;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
12 Not yet recruiting A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Conditions: Acute Lymphoblastic Leukemia;   B-cell Non Hodgkin Lymphoma;   Pre B-Cell Acute Lymphoblastic Leukaemia
Interventions: Drug: Blinatumomab;   Drug: Dexamethasone
13 Not yet recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Conditions: Activated B-Cell-Like Diffuse Large B-Cell Lymphoma;   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly;   Epstein-Barr Virus-Positive Mucocutaneous Ulcer;   Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma;   High-Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   Human Herpesvirus-8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   MYC-Negative B-Cell Lymphoma With 11q Aberration Resembling Burkitt Lymphoma;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Skin Ulcer;   Small Intestinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Varlilumab
14 Recruiting Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Conditions: Grade 3a Follicular Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Waldenstrom Macroglobulinemia;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Nivolumab
15 Recruiting Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk
Condition: B-cell Acute Lymphoblastic Leukemia
Intervention:
16 Recruiting Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Lymphoma,Non-Hodgkin;   Lymphoma, Hodgkin;   Lymphoma, Follicular;   Marginal Zone Lymphoma;   Large Cell Lymphoma;   Mantle-Cell Lymphoma;   Gray Zone Lymphoma;   Burkitt Lymphoma
Interventions: Drug: Bendamustine;   Drug: Cyclophosphamide
17 Recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Drug: Lenalidomide;   Biological: Obinutuzumab;   Drug: Venetoclax
18 Recruiting Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Mediastinal Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Waldenstrom Macroglobulinemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
19 Recruiting The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Condition: B-cell Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CART-19 cells
20 Recruiting Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Conditions: B-Cell Non-Hodgkin Lymphoma;   Chemotherapy-Related Nausea and/or Vomiting;   Childhood Acute Myeloid Leukemia;   Childhood Burkitt Lymphoma;   Childhood Neoplasm;   Febrile Neutropenia;   Hematopoietic Cell Transplantation Recipient;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Informational Intervention;   Other: Interview;   Other: Medical Chart Review

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.